This marks a significant milestone as SIGX1094 is the first pipeline drug discovered using AI and organoid disease model to enter clinical trials, and the first targeted therapy candidate to ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Okomera is a biotech startup developing cutting-edge solutions for oncology drug discovery and will present their technology in SLAS 2025,in San Diego January 25 to 29, 2025. Okomera will showcase its ...

If we can develop methods that we can readily apply to better models that reflect the patient’s disease, then we will vastly increase the quality of data we generate and eventually identify better ...

with limited studies on organoid functionality. For effective drug evaluation and precise biological research, technology that preserves the three-dimensional structure of organoids while enabling ...

These models offer a promising alternative to animal testing and address key challenges in dermatological drug testing, ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Bioinformatics allowed me to address these questions faster and with a broader perspective. The growing availability of public data facilitated this. However, the transition wasn’t easy. I tried many ...

Brain organoids developed in Israel for testing and repurposing a wide variety of existing drugs to see if they could treat ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...